X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with TTK HEALTHCARE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs TTK HEALTHCARE - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. TTK HEALTHCARE FRESENIUS KABI ONCO./
TTK HEALTHCARE
 
P/E (TTM) x 22.1 16.8 131.9% View Chart
P/BV x 3.1 5.5 57.0% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 FRESENIUS KABI ONCO.   TTK HEALTHCARE
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
TTK HEALTHCARE
Mar-14
FRESENIUS KABI ONCO./
TTK HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs176663 26.5%   
Low Rs79399 19.7%   
Sales per share (Unadj.) Rs37.7535.6 7.0%  
Earnings per share (Unadj.) Rs5.115.9 31.9%  
Cash flow per share (Unadj.) Rs6.720.0 33.6%  
Dividends per share (Unadj.) Rs04.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs42.5137.6 30.9%  
Shares outstanding (eoy) m158.237.77 2,036.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.41.0 340.5%   
Avg P/E ratio x25.033.3 75.0%  
P/CF ratio (eoy) x18.926.5 71.4%  
Price / Book Value ratio x3.03.9 77.5%  
Dividend payout %025.1 0.0%   
Avg Mkt Cap Rs m20,1354,127 487.8%   
No. of employees `0001.21.7 67.4%   
Total wages/salary Rs m703607 115.9%   
Avg. sales/employee Rs Th5,176.22,436.7 212.4%   
Avg. wages/employee Rs Th610.4355.2 171.9%   
Avg. net profit/employee Rs Th699.672.5 964.4%   
INCOME DATA
Net Sales Rs m5,9634,162 143.3%  
Other income Rs m1861 29.4%   
Total revenues Rs m5,9814,223 141.6%   
Gross profit Rs m1,430197 725.6%  
Depreciation Rs m25832 813.6%   
Interest Rs m-2630 -87.0%   
Profit before tax Rs m1,216197 618.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m34273 470.1%   
Profit after tax Rs m806124 650.4%  
Gross profit margin %24.04.7 506.4%  
Effective tax rate %28.137.0 76.0%   
Net profit margin %13.53.0 454.0%  
BALANCE SHEET DATA
Current assets Rs m5,1021,629 313.2%   
Current liabilities Rs m2,3851,058 225.5%   
Net working cap to sales %45.613.7 332.1%  
Current ratio x2.11.5 138.9%  
Inventory Days Days15030 503.9%  
Debtors Days Days11334 337.3%  
Net fixed assets Rs m5,148556 925.4%   
Share capital Rs m15878 203.6%   
"Free" reserves Rs m6,556878 746.4%   
Net worth Rs m6,7321,069 629.6%   
Long term debt Rs m952159 600.0%   
Total assets Rs m10,3882,399 432.9%  
Interest coverage x-45.87.6 -604.0%   
Debt to equity ratio x0.10.1 95.3%  
Sales to assets ratio x0.61.7 33.1%   
Return on assets %7.56.4 117.1%  
Return on equity %12.011.6 103.3%  
Return on capital %14.618.5 79.1%  
Exports to sales %74.50.8 9,420.2%   
Imports to sales %24.81.4 1,768.7%   
Exports (fob) Rs m4,44133 13,497.3%   
Imports (cif) Rs m1,47758 2,534.1%   
Fx inflow Rs m5,29833 16,102.1%   
Fx outflow Rs m1,77263 2,804.6%   
Net fx Rs m3,525-30 -11,638.8%   
CASH FLOW
From Operations Rs m1,274127 1,006.4%  
From Investments Rs m-1,204-146 824.8%  
From Financial Activity Rs m-19622 -895.4%  
Net Cashflow Rs m-1263 -5,052.0%  

Share Holding

Indian Promoters % 0.0 65.4 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 3.7 8.1%  
FIIs % 9.6 5.2 184.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 25.8 35.3%  
Shareholders   42,599 12,723 334.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   TORRENT PHARMA  NATCO PHARMA  AJANTA PHARMA  SANOFI INDIA  ALEMBIC PHARMA  

Compare FRESENIUS KABI ONCO. With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Prepare to Ride Out Volatile Markets with Rahul Shah(Podcast)

Watching the stock market basically volatile on a regular basis isn't easy. Catch Rahul Shah talk about his mantra to ride out the volatility in times like these.

Related Views on News

TTK HEALTHCARE Announces Quarterly Results (2QFY19); Net Profit Down 15.3% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, TTK HEALTHCARE has posted a net profit of Rs 67 m (down 15.3% YoY). Sales on the other hand came in at Rs 2 bn (up 16.3% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

TTK HEALTHCARE Announces Quarterly Results (1QFY19); Net Profit Down 276.0% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, TTK HEALTHCARE has posted a net profit of Rs 79 m (down 276.0% YoY). Sales on the other hand came in at Rs 2 bn (up 38.1% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Why Qualitative Aspects Are So Important To Pick Mutual Funds(Outside View)

Nov 26, 2018

PersonalFN briefly outlines why qualitative parameters are equally important in selecting mutual funds.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. - NATCO PHARMA COMPARISON

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS